India's drug regulator CDSCO has found 53 drugs to be of non-standard quality in its latest test, which includes popular medicines like paracetamol, Vitamin D supplements, and antibiotics. These drugs are manufactured by various companies, including state-owned Hindustan Antibiotics. Some of these medicines were also linked to the deaths of 12 children in J&K in 2020, prompting tighter quality inspection measures in Gambia. In response to these findings, the CDSCO has revoked the power of state and UT authorities to grant no-objection-certificates for export purposes, and companies who received approvals in the past will have to report them to the central drug regulators. Stay updated with Fortune India on social media for more updates.
India Uncovers Substandard Drugs, Prompting Stringent Inspections
The Central Drugs Standard Control Organization (CDSCO), India's drug regulator, has exposed a startling trend in the country's pharmaceutical industry: 53 drugs of subpar quality. This discovery has sent shockwaves through the medical community and has led to heightened concerns about the safety of medications available to the public.
Background
India is a major player in the global pharmaceutical market, exporting drugs to over 200 countries. However, the revelation of substandard drugs raises questions about the quality control and regulatory oversight of the industry. In the past, India has been plagued by drug scandals involving fake and adulterated medicines.
The Latest Findings
The 53 subpar drugs include popular medicines such as paracetamol, Vitamin D supplements, and antibiotics. They were manufactured by various companies, including state-owned Hindustan Antibiotics. Some of the affected medicines were reportedly linked to the deaths of 12 children in Jammu and Kashmir in 2020.
Response from CDSCO
In light of these findings, the CDSCO has taken swift action:
Top 5 FAQs and Answers
1. What is the concern with the substandard drugs?
Answer: The drugs may not meet appropriate standards of purity, potency, or efficacy, potentially compromising patient safety.
2. Why were the drugs declared substandard?
Answer: The CDSCO conducted tests and found discrepancies in the composition, disintegration times, and other quality parameters.
3. What is being done to address the issue?
Answer: The CDSCO is conducting further investigations and revoking export approvals for affected companies. The government is also considering strengthening regulatory oversight of the pharmaceutical industry.
4. What should patients do if they have been taking the affected drugs?
Answer: Patients should consult with their healthcare providers to discuss alternative medications or further monitoring.
5. What measures are being taken to prevent future incidents?
Answer: The CDSCO is implementing stricter quality control procedures, increasing inspections, and considering enhanced penalties for manufacturers found in violation.
Conclusion
The discovery of substandard drugs in India highlights the importance of vigilant oversight and stringent regulation in the pharmaceutical industry. The CDSCO's swift response and the government's commitment to strengthen quality control measures demonstrate a determination to protect public health and ensure the safety of medications used by the nation's citizens.
TCS, the Mumbai-based IT giant, has released its Q3 results for FY 2025, showcasing impressive numbers and highlighting the company's commitment to employee development and recruitment. With over 1,10,000 promotions and a diverse workforce of 152 nationalities, TCS continues to invest in upskilling and well-being of its employees. Despite cross-currency volatility, TCS's financial discipline and strategic investments have led to positive margins and free cash flows, ensuring long-term business growth.
Mahindra, one of the leading players in the EV market, has added another feather to its cap with the launch of the XEV 9e at an affordable price of Rs 21.9 Lakh Ex-Showroom. With a range of 542 km on a single charge and a powerful engine delivering 228 bhp and 380 Nm of torque, the XEV 9e is a well-balanced and premium offering that is sure to impress both EV enthusiasts and regular car buyers alike. To get a taste of the driving experience, check out the video below.
The electric SUV market in India is growing with the launch of new models from Tata, Mahindra, and Hyundai. This article provides a comparison of the variants and prices of the Mahindra BE6, XEV 9e, and Tata Curvv, to help customers make an informed decision in their budget. Test drives of the vehicles will be available in a staggered manner, starting with metropolitan cities and expanding to other cities in phases.
After creating a buzz on social media, Mahindra has now announced the prices for their top models BE 6 and XEV 9e. Priced at Rs 18.9 and Rs 26.9 lakh respectively, both models can be pre-booked from February 14, 2025. Interested customers can also test drive them starting from January 14 in select cities. The BE 6 offers an impressive range and fast charging capabilities, making it a promising offering from Mahindra.
The University Grants Commission is seeking suggestions and comments from stakeholders on its proposed draft regulations for the appointment and promotion of teachers and academic staff in universities and colleges. The regulations aim to update and harmonize guidelines for academic positions across all higher education institutions in India, and will introduce new methodologies for recruitment and promotion processes. Stakeholders are urged to review the draft and contribute to the shaping of the future of academic staffing in the country.
The Indian Health Ministry is taking action as the number of HMPV cases rises to five, with two patients in Tamil Nadu and none so far in Maharashtra. The 2019 outbreak began with two infants in Bengaluru but only one remains hospitalized. The respiratory illness has flu-like symptoms such as common cold, sore throat, and fever and the ministry has directed state health officials to monitor any SARI or ILI cases. Haryana's health minister has issued an advisory for civil surgeons in regards to respiratory diseases including HMPV.
The stock market saw a sharp decline on Tuesday, with the S&P 500 and Nasdaq Composite falling 0.9% and 1.6%, respectively. This was fueled by a rise in the yield of 10-year Treasurys, indicating concerns about the future of interest rates. The release of strong economic data, including better-than-expected job openings in November, also raised questions about the Fed's decision-making on rates. The tech sector was hit hard, with AI chipmaker Nvidia's stock dropping 5% after hitting an all-time high earlier in the day.
In an interesting turn of events, users of X (formerly Twitter) discovered a "X Score" feature that was touted to provide an insight into their social credit standing on the platform. However, most users were shocked when the AI assistant gave them a paltry 38 out of 100. This led to speculations of a possible algorithm tweak by X's owner Elon Musk, but later it was revealed that this was not an official feature and no changes had been made to the algorithm. So, if you're wondering why your views are going down, Musk has a simple answer for you.
Nazibur Rahman, former principal secretary to the Prime Minister's Office and National Board of Revenue chairman, has been sent to jail after his three-day remand in connection with the 2022 killing of a BNP activist. Police have implicated Rahman in the case after arresting him in October 2025. The incident began when BNP leaders and activists gathered in the capital as part of their party program. On December 7, 2022, police and AL men entered the BNP office and opened fire, injuring the activist. A case has been filed against 256 people, including Prime Minister Sheikh Hasina, for their involvement in the incident.
In a major shift, Facebook, Instagram, and Threads will no longer use fact-checkers to moderate content, instead relying on community notes similar to X. The move is intended to promote free speech and reduce mistakes in content moderation. Additionally, the company will be moving its trust and safety teams responsible for content policies and moderation from California to Texas and scrapping restrictions on topics like immigration and gender identity. However, there is a trade-off as the company admits it will catch less bad content but also reduce the number of innocent posts and accounts that are accidentally removed.